Özdemir Başer Özden, Göçmen Ayşe Yeşim, Aydoğan Kırmızı Demet
Yozgat City Hospital, Clinic of Endocrinology and Metabolism, Yozgat, Turkey.
Yozgat Bozok University Faculty of Medicine, Department of Biochemistry, Yozgat, Turkey.
Turk J Obstet Gynecol. 2022 Sep 23;19(3):229-235. doi: 10.4274/tjod.galenos.2022.29498.
The relationship between Cystatin-C levels and inflammatory, oxidant, and antioxidant markers in polycystic ovary syndrome (PCOS) was investigated.
A total of 96 participants were included in the study as PCOS (n=58) and control (n=38) groups. Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1B), interleukin 6 (IL-6), malondialdehyde (MDA), superoxide dismutase (SOD), and Cystatin-C were evaluated by ELISA method. Relationships metabolic and endocrine parameters seen in PCOS were examined. Univariate and multivariate logistic regression analyzes were performed to identify risk factors that may affect the PCOS group. Bivariate correlations were investigated by the Spearman's correlation analysis.
While Cystatin-c, TNF-α, IL-1B, IL-6, MDA were found to be higher in patients with PCOS compared with the control group, SOD was found to be lower than the control group (p<0.05). In the correlation analysis, increased Cystatin-C levels were found to be associated with high IL-6 (r=0.214, p=0.037) and low SOD levels (r=-0.280, p=0.006).
In our study, it was found that the increase in Cystatin-C levels was associated with an increase in IL-6 and a decrease in SOD. These results may bring up different treatment options to reduce cardiovascular risks for treating PCOS.
研究多囊卵巢综合征（PCOS）患者胱抑素-C水平与炎症、氧化及抗氧化标志物之间的关系。
本研究共纳入96名参与者，分为PCOS组（n = 58）和对照组（n = 38）。采用酶联免疫吸附测定法（ELISA法）评估肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1B）、白细胞介素6（IL-6）、丙二醛（MDA）、超氧化物歧化酶（SOD）和胱抑素-C。检测PCOS患者的代谢和内分泌参数。进行单因素和多因素逻辑回归分析以确定可能影响PCOS组的危险因素。采用Spearman相关分析研究双变量相关性。
与对照组相比，PCOS患者的胱抑素-C、TNF-α、IL-1B、IL-6、MDA水平较高，而SOD水平低于对照组（p < 0.05）。在相关性分析中，发现胱抑素-C水平升高与高IL-6（r = 0.214，p = 0.037）和低SOD水平（r = -0.280，p = 0.006）相关。
在我们的研究中，发现胱抑素-C水平升高与IL-6升高和SOD降低有关。这些结果可能为降低PCOS患者心血管风险带来不同的治疗选择。
